Initiation & Execution of Early Oncology Clinical Trials in the Time of COVID-19

Presented by

Luke Gill, B.Sc. (Hon), M.Sc., MBA and Peter Larson, M.D.

About this talk

Initiation and Execution of Early Oncology Clinical Trials in the Time of COVID-19 Early-phase oncology, emerging from the crisis, and research and innovation for the future As the world emerges from the pandemic of novel coronavirus disease (COVID-19), the treatment need for cancer patients is greater than ever. Join Premier Research’s upcoming webinar to learn how to manage ongoing cell and gene therapy (CAGT) trials. We will share Premier’s real-time clinical insights into conducting early-phase oncology and CAGT trials during the COVID-19 crisis to help you plan for future success. We will explore how CAGT is being applied to treating tumors and discuss key study design and operational considerations for new early-phase oncology trials. Finally, we will review the impact of COVID-19 on the CAGT clinical trial environment and share lessons learned in this new emerging reality. Key takeaways: • Gain an understanding of the science and pathophysiology associated with CAGT • Review key trial design considerations for CAGT in solid and liquid tumors and potential telemedicine options • Get an overview of new CAGT products in development and their impact on clinics during and post-COVID-19 • Discuss regulatory agency guidance, operational issues, and strategies to streamline procedures Speakers: Luke Gill, B.Sc. (Hon), M.Sc., MBA Vice President and Head of Oncology Clinical Development Service Peter Larson, M.D. Executive Medical Director

Related topics:

More from this channel

Upcoming talks (1)
On-demand talks (65)
Subscribers (2772)
Premier Research is a clinical research company, dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments. As a global company, Premier specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors. Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.